How to buy Acorda Therapeutics (ACOR) shares in the UK

Learn how to easily invest in Acorda Therapeutics shares.

Acorda Therapeutics Inc
- $0.13 ( - 2.85%)

Acorda Therapeutics Inc (ACOR) is a leading biotechnology business based in the US. It opened the day at $5.16 after a previous close of $5.19. During the day the price has varied from a low of $5.1046 to a high of $5.28. The latest price was $5.23 (25 minute delay). Acorda Therapeutics is listed on the NASDAQ and employs 167 staff. All prices are listed in US Dollars.

How to buy shares in Acorda Therapeutics

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: ACOR in this case.
  5. Research Acorda Therapeutics shares. The platform should provide the latest information available.
  6. Buy your Acorda Therapeutics shares. It's that simple.
The whole process can take as little as 15 minutes.

How has coronavirus impacted Acorda Therapeutics's share price?

Since the stock market crash that started in February 2020, Acorda Therapeutics's share price has had significant negative movement.

Its last market close was $4.61, which is 49.45% down on its pre-crash value of $9.12 (accounting for the 3 January 2021 split) and 9.76% up on the lowest point reached during the March 2020 crash when the shares fell as low as $4.2 (accounting for the 3 January 2021 split).

If you had bought $1,000 worth of Acorda Therapeutics shares at the start of February 2020, those shares would have been worth $430.24 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $378.48.

Acorda Therapeutics share price (NASDAQ:ACOR)

Use our graph to track the performance of ACOR stocks over time.

Acorda Therapeutics shares at a glance

Information last updated 2021-06-28.
Previous close$5.19
Change %0.7707%
Information last updated 2021-10-16.
52-week range$3.27 - $8.66
50-day moving average$4.4635
200-day moving average$4.2776
Wall St. target price$10
Dividend yieldN/A (0%)
Earnings per share (TTM)$-14.723
eToro Free Stocks

Invest in Acorda Therapeutics shares with 0% commission

Other fees apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • Pay no stamp duty on UK shares (saving 0.5%)
  • Create an account today in a few minutes
Capital at risk

Fees for buying 100x Acorda Therapeutics shares with popular platforms

Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
Freetrade logo £0 No minimum £1.70
£379.78 total
Capital at risk
eToro Free Stocks logo £0 $50 £1.89
£379.97 total
Capital at risk
Fineco logo £0 No minimum £3.78
£381.86 total
Capital at risk
Degiro Share Dealing logo £0 £0.01 £1.09
£379.17 total
Capital at risk
Stake logo £0 £50 £2.18
£380.26 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £16.02
£394.10 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £13.95
£392.03 total
Capital at risk
Halifax Share Dealing Account logo £36 per year £20 £14.52
£392.59 total
Capital at risk

Full comparison of share dealing platforms

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy Acorda Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Acorda Therapeutics price performance over time

Historical closes compared with the last close of $5.23

1 week (2021-10-13) 12.96%
1 month (2021-09-20) 19.95%
3 months (2021-07-20) 39.47%
6 months (2021-04-20) 26.02%
1 year (2020-10-20) -9.39%
2 years (2019-10-18) -64.57%
3 years (2018-10-19) -95.12%
5 years (2016-10-20) -95.68%

Is Acorda Therapeutics under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

PEG ratio

Acorda Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.51. A PEG ratio below 1 can be interpreted as meaning the shares are not overvalued given the current rate of growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Acorda Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

However, it's sensible to consider Acorda Therapeutics's PEG ratio in relation to those of similar companies.


    Revenue TTM $151.9 million
    Gross profit TTM $96.8 million
    Return on assets TTM -8.1%
    Return on equity TTM -54.85%
    Profit margin -86.91%
    Book value $17.15
    Market capitalisation $52.4 million

    TTM: trailing 12 months

    How to short and sell Acorda Therapeutics shares

    1. Create a CFD or spread betting account.
    2. Search for the stock code. E.g. "ACOR.US"
    3. Choose your position size.
    4. Select "sell" rather than "buy".
    5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

    There are currently 570,372 Acorda Therapeutics shares held short by investors – that's known as the "short interest". This figure is 24.7% down from 757,862 last month.

    There are a few different ways that this level of interest in shorting Acorda Therapeutics shares can be evaluated.

    Short interest ratio (SIR)

    Acorda Therapeutics's "short interest ratio" (SIR) is the quantity of Acorda Therapeutics shares currently shorted divided by the average quantity of Acorda Therapeutics shares traded daily (recently around 138104.60048426). Acorda Therapeutics's SIR currently stands at 4.13. In other words for every 100,000 Acorda Therapeutics shares traded daily on the market, roughly 4130 shares are currently held short.

    To gain some more context, you can compare Acorda Therapeutics's short interest ratio against those of similar companies.

    However Acorda Therapeutics's short interest can also be evaluated against the total number of Acorda Therapeutics shares, or, against the total number of tradable Acorda Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Acorda Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Acorda Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0612% of the tradable shares (for every 100,000 tradable Acorda Therapeutics shares, roughly 61 shares are currently held short).

    Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Acorda Therapeutics.

    Find out more about how you can short Acorda Therapeutics stock.

    Acorda Therapeutics share dividends

    We're not expecting Acorda Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

    Have Acorda Therapeutics's shares ever split?

    Acorda Therapeutics's shares were split on a 1:6 basis on 3 January 2021. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Acorda Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Acorda Therapeutics shares which in turn could have impacted Acorda Therapeutics's share price.

    Share price volatility

    Over the last 12 months, Acorda Therapeutics's shares have ranged in value from as little as $3.27 up to $8.66. A popular way to gauge a stock's volatility is its "beta".

    ACOR.US volatility(beta: 0.58)Avg. volatility(beta: 1.00)LowHigh

    Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acorda Therapeutics's is 0.5799. This would suggest that Acorda Therapeutics's shares are less volatile than average (for this exchange).

    To put Acorda Therapeutics's beta into context you can compare it against those of similar companies.

    Win £500 to get your trading started

    Subscribe to trending stock alerts for a chance to win

    By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

    Shares similar to Acorda Therapeutics

    Frequently asked questions

    More guides on Finder

    Ask an Expert

    You are about to post a question on

    • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
    • is a financial comparison and information service, not a bank or product provider
    • We cannot provide you with personal advice or recommendations
    • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

    By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

    Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
    Go to site